tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

AGIO Stock Latest News

Agios Pharmaceuticals announces FDA granted ODD to AG-946
The FlyAgios Pharmaceuticals announces FDA granted ODD to AG-946
9d ago
AGIO
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)
PremiumPress Releases
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)
9d ago
AGIO
Agios Pharmaceuticals’ treatment of myelodysplastic syndromes gets orphan status
PremiumThe Fly
Agios Pharmaceuticals’ treatment of myelodysplastic syndromes gets orphan status
10d ago
AGIO
Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024
PremiumPress Releases
Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024
15d ago
AGIO
Closing Bell Movers: Airbnb, TripAdvisor down double digits on earnings
PremiumThe Fly
Closing Bell Movers: Airbnb, TripAdvisor down double digits on earnings
1M ago
GO
EBS
Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib
PremiumPress ReleasesAgios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib
1M ago
AGIO
Agios to receive $1.1B in milestone payments after FDA approval of vorasidenib
Premium
The Fly
Agios to receive $1.1B in milestone payments after FDA approval of vorasidenib
1M ago
AGIO
Agios Pharmaceuticals reports results from Phase 3 ACTIVATE-KidsT study
Premium
The Fly
Agios Pharmaceuticals reports results from Phase 3 ACTIVATE-KidsT study
2M ago
AGIO
Agios Pharmaceuticals reports Q2 EPS ($1.69), consensus ($1.60)
PremiumThe Fly
Agios Pharmaceuticals reports Q2 EPS ($1.69), consensus ($1.60)
2M ago
AGIO
Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused
PremiumPress Releases
Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused
2M ago
AGIO
Agios Reports Business Highlights and Second Quarter 2024 Financial Results
PremiumPress Releases
Agios Reports Business Highlights and Second Quarter 2024 Financial Results
2M ago
AGIO
AGIO Earnings this Week: How Will it Perform?
PremiumPre-Earnings
AGIO Earnings this Week: How Will it Perform?
2M ago
AGIO
Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024
PremiumPress ReleasesAgios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024
2M ago
AGIO
Royalty Pharma price target raised to $51 from $48 at Morgan Stanley
Premium
The Fly
Royalty Pharma price target raised to $51 from $48 at Morgan Stanley
2M ago
AGIO
PTCT
JPMorgan biotech analysts hold an analyst/industry conference call
Premium
The Fly
JPMorgan biotech analysts hold an analyst/industry conference call
3M ago
AGIO
BLUE
Agios Pharmaceuticals presents results from Phase 3 ENERGIZE study of mitapivat
PremiumThe Fly
Agios Pharmaceuticals presents results from Phase 3 ENERGIZE study of mitapivat
3M ago
AGIO
Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress
PremiumPress Releases
Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress
3M ago
AGIO
Intellia Therapeutics appoints Brian Goff to board of directors
PremiumThe Fly
Intellia Therapeutics appoints Brian Goff to board of directors
3M ago
AGIO
NTLA
Agios Pharmaceuticals reinstated with a Neutral at JPMorgan
PremiumThe Fly
Agios Pharmaceuticals reinstated with a Neutral at JPMorgan
3M ago
AGIO
Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET
PremiumPress ReleasesUpdated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET
4M ago
AGIO
Agios Pharmaceuticals price target raised to $53 from $44 at RBC Capital
Premium
The Fly
Agios Pharmaceuticals price target raised to $53 from $44 at RBC Capital
4M ago
AGIO
RPRX
Agios reports Phase 3 ENERGIZE-T study of mitapivat met primary endpoint
Premium
The Fly
Agios reports Phase 3 ENERGIZE-T study of mitapivat met primary endpoint
4M ago
AGIO

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >